Viewing data from:

IMIPRAMINE PAMOATE

ANDA

IMIPRAMINE PAMOATE | A090444 | LUPIN LTD

4 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Imipramine Pamoate (2023)

Total Spending

$3.1M

Total Claims

5,949

Beneficiaries

1,234

Avg Cost/Unit

$8.15

Spending Trend

$4.0M(2019)→$3.7M(2020)→$3.5M(2021)→$3.2M(2022)→$3.1M(2023)

YoY Change:-1.7%

5yr CAGR:-0.6%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain3 active DMFs6 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

RL FINE CHEM PVT LTDIMIPRAMINE PAMOATE DRUG SUBSTANCE

DMF 196122006

LUPIN LTDIMIPRAMINE PAMOATE USP

DMF 214932008

LUNDBECK PHARMACEUTICALS ITALY SPAIMIPRAMINE PAMOATE

DMF 221042008

VIS FARMACEUTICAInactiveIMIPRAMINE PAMOATE

DMF 53221984

SELOC AGInactiveIMIPRAMINE PAMOATE

DMF 67631986

SCHWIEZERHALL DEVELOPMENT COInactiveIMIPRAMINE PAMOATE

DMF 141501999

PISGAH LABS INCInactiveIMIPRAMINE PAMOATE

DMF 153592001

R L FINE CHEMInactiveIMIPRAMINE PAMOATE

DMF 188012005

FARCHEMIA SRLInactiveIMIPRAMINE PAMOATE

DMF 230762009

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (4)

Sort:

#001 — EQ 75MG HYDROCHLORIDE

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Apr 16, 2010

No patent or exclusivity listings for this strength.

#002 — EQ 100MG HYDROCHLORIDE

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Apr 16, 2010

#003 — EQ 125MG HYDROCHLORIDE

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Apr 16, 2010

#004 — EQ 150MG HYDROCHLORIDE

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Apr 16, 2010